ReviewCurrent opinion in pharmacology2018
Recent advances in combinatorial drug screening and synergy scoring.
Review in Current opinion in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 126 citations in OpenAlex.
- Article
- Personalizing chemotherapy drug selection using a novel transcriptomic chemogram.PLoS computational biology · 2025Article
- Article
- AI-driven high-throughput droplet screening of cell-free gene expression.Nature communications · 2025Article
- Scaling up drug combination surface prediction.Briefings in bioinformatics · 2025Article
- Predicting drug combination response surfaces.npj drug discovery · 2025Article
- Predicting drug combination side effects based on a metapath-based heterogeneous graph neural network.BMC bioinformatics · 2025Article
- Biofabrication of copper oxide nanoparticles using Dalbergia sisso leaf extract for antibacterial, antibiofilm and antioxidant activities.Scientific reports · 2024Article
- Cancer Cell's Achilles Heels: Considerations for Design of Anti-Cancer Drug Combinations.International journal of molecular sciences · 2024Article
- Multitarget Phytocomplex: Focus on Antibacterial Profiles of Grape Pomace andAntibiotics (Basel, Switzerland) · 2024Article
- Synergistic Enhancement of Chemotherapy-Induced Cell Death and Antitumor Efficacy against Tumoral T-Cell Lymphoblasts by IMMUNEPOTENT CRP.International journal of molecular sciences · 2024Article
- Article
- Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.British journal of cancer · 2024Review
- Andrographolide acts with dexamethasone to inhibit the growth of acute lymphoblastic leukemia CEM‑C1 cells via the regulation of the autophagy‑dependent PI3K/AKT/mTOR signaling pathway.Biomedical reports · 2024Article
- Evaluation of Novel HLM Peptide Activity and Toxicity against Planktonic and Biofilm Bacteria: Comparison to Standard Antibiotics.Current protein & peptide science · 2024Article
- Computational Advancements in Cancer Combination Therapy Prediction.JCO precision oncology · 2023Article
- Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.World journal of gastroenterology · 2023Review
- The bovine dialyzable leukocyte extract, immunepotent CRP, synergically enhances cyclophosphamide-induced breast cancer cell death, through a caspase-independent mechanism.EXCLI journal · 2023Article
- Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies.Frontiers in pharmacology · 2023Article
- First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.Journal of medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of complex diseases such as cancer, cardiovascular disease, diabetes or neurological disorders frequently warrants the utilization of drug combinations for therapeutic intervention. In fact, the most successful example is the current standard of care for HIV patients. However, identification of successful drug cocktails is not a simple task and is hampered by lack of standardization in terminology, experimental protocols and models as well as data analysis. Here we discuss the most recent developments in combinatorial drug screening by covering technological advancements in screening strategies, cellular model systems as well as novel drug classes. We believe the research progress being made provides promising basis to build on and identify, develop and optimize efficacious clinically relevant combinatorial drug treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.